Axcelead Drug Discovery Partners, Inc.’s Post

Today we announced groundbreaking enzymatic synthesis data at the #TIDESUSA annual meeting! Codexis has successfully synthesized a full-length, known siRNA oligonucleotide from starting material through the attachment of a conjugation moiety via an enzymatic route to support RNA-based therapeutics manufacturing. RNAi therapeutics key opinion leader John Maraganore noted, “The data presented today by Codexis are truly unprecedented—I believe this is the first enzymatic synthesis of a full-length oligonucleotide from starting material through the attachment of a conjugation moiety. This milestone provides meaningful proof of process to industry that there are alternative manufacturing methods available as the demand for RNAi therapeutics increases. The ECO Synthesis™ manufacturing platform has the potential to be a scalable and sustainable way to manufacture this important and growing new class of medicines.” Read our press release for more information: https://lnkd.in/d9WquAUY #enzymeengineering #proteinengineering #RNAi #RNAimanufacturing #enzymaticsynthesis

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚 𝐔𝐩𝐝𝐚𝐭𝐞𝐬: September 18 - 19, 2024 • GC Therapeutics launches with $75M to revolutionize cell therapy • Roche’s positive antiviral Ph3 data • Tanai Therapeutics’ obesity endeavours further fuelled by Novo Nordisk • Upstream Bio files for IPO • Basilea Pharmaceutica extends BARDA partnership • Vanda Pharmaceuticals' gastroparesis small molecule rejected by FDA • Biotech small-cap market goes “meh” on US Fed rate cut • Achilles Therapeutics plc axes TIL-based therapy program • Study finds new-gen migraine meds not much better than OTC regulars (eg. tylenol, aspirin) More in today's TLDR Biotech newsletter: https://lnkd.in/g5XN9hre #biotech #pharma #pharmanews #biotechnews #tldrbiotech

🚀 Kicking off Day 2 of the 20th BioPharma Drug Discovery Nexus Conference with a bang! Join Mauro Mileni Founder and CEO, Abilita Therapeutics, Inc. as he unveils insights into 'Enabling the Discovery of Therapeutic Antibodies Targeting Challenging Membrane Proteins'. Don't miss out on this enlightening session! #BioPharma #DrugDiscovery #Innovation #Antibodies #Therapeutics #Membraneproteins #Epitopes #Conformational #Protiens #NexusConference #SanDiego #USconference #ScientificConference

Neurogenic Detrusor Overactivity Treatment Market Size in the 7MM is expected to witness a major change in the study period 2020-2034: Neurogenic Detrusor Overactivity Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Neurogenic Detrusor Overactivity Therapeutics includes promising candidates that aim … Continue reading → #PharmaceuticalsBiotech

📢  Pfizer has announced the discontinuation of OXBRYTA for Sickle Cell Disease (SCD) in all approved markets after data indicated a higher risk of vaso-occlusive crises and fatal events, which they consider outweigh the benefits of the treatment. ❗️This comes as a major blow for the company after having acquired the originator, Global Blood Therapeutics, for $5.4B in 2022. Regardless, Pfizer will push ahead with its other SCD candidates. ➡️ This decision may also serve as a potential catalyst for CRISPR Therapeutics and Vertex Pharmaceuticals' CASGEVY, the first approved Cas9 gene-edited therapy for SCD. 🌟 The future of SCD treatment is evolving rapidly, and gene-editing therapies could represent a significant advancement in early detection and management. #SickleCellDisease #GeneTherapy #CRISPR #Pfizer #Biotech

Clene Nanomedicine, Inc.., a biopharmaceutical company focused on improving mitochondrial health and treating neurodegenerative diseases, will meet with the U.S. Food and Drug Administration (FDA) before the end of November 2024. The meeting will discuss the development of Clene's proprietary CNM-Au8 for the treatment of amyotrophic lateral sclerosis (ALS). The FDA representatives attending the meeting will include the director of the Office on New Drugs, the director of the Office of Neuroscience, the Division of Neurology 1 review team, and key opinion leaders in ALS, biostatistics, and biomarkers. 'CNM-Au8 is an investigational, first-in-class therapy that improves the survival and function of central nervous system cells via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress,' the company stated. Clene, based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, is focused on developing treatments for neurodegenerative diseases like ALS, Parkinson's disease, and multiple sclerosis. #neurodegenerativediseases #als #fda @cleneinc @fdanews

𝐍𝐞𝐰𝐬 𝐚𝐛𝐨𝐮𝐭 𝐈𝐧𝐭𝐚𝐯𝐢𝐬 𝐏𝐞𝐩𝐭𝐢𝐝𝐞 𝐒𝐞𝐫𝐯𝐢𝐜𝐞𝐬 Personalize medicine based on peptide has made great progress in recent years. As more and more clinical projects were initiated the demand for small scale GMP grade peptides was also picking up quickly. Hence, Intavis Peptide Services decided in 2019 to build 𝐚 𝐆𝐌𝐏 𝐀𝐏𝐈 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐲. Lo and behold, we are on schedule and eagerly await the opening ceremonies planned for Q4 of 2024. If you are you planning any 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥𝐬 𝐨𝐧 𝐩𝐞𝐩𝐭𝐢𝐝𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬, don’t hesitate to check out 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞. #gmp #drugdevelopment #peptides #clinicaltrials #intavis

🧬💊 Find Research-Grade Biosimilars Easily in One Place! Are you tired of sifting through endless product lists to find the perfect biosimilar for your research? We've got good news! Now you can search through our research-grade biosimilars offering effortlessly on our website. Biosimilar antibodies for research enable cost-effective study of drug effects, bypassing the need for expensive pharmaceutical-grade therapeutics. They are crucial for validating novel treatments and offer significant value in fields like immuno-oncology and autoimmunity. Simply input the keyword "Biosimilar" into the search bar on our website to access the complete list of such products. The new Biosimilar search is designed to make your search process seamless and efficient. Dive into our wide range of biosimilars today and push the boundaries of your research. https://lnkd.in/g-5rmFJa #Thermofisherscientific #research #antibodies #biosimilars

🧬💊 Find Research-Grade Biosimilars Easily in One Place! Are you tired of sifting through endless product lists to find the perfect biosimilar for your research? We've got good news! Now you can search through our research-grade biosimilars offering effortlessly on our website. Biosimilar antibodies for research enable cost-effective study of drug effects, bypassing the need for expensive pharmaceutical-grade therapeutics. They are crucial for validating novel treatments and offer significant value in fields like immuno-oncology and autoimmunity. Simply input the keyword "Biosimilar" into the search bar on our website to access the complete list of such products. The new Biosimilar search is designed to make your search process seamless and efficient. Dive into our wide range of biosimilars today and push the boundaries of your research. https://lnkd.in/g-5rmFJa #Thermofisherscientific #research #antibodies #biosimilars

🧬💊 Find Research-Grade Biosimilars Easily in One Place! Are you tired of sifting through endless product lists to find the perfect biosimilar for your research? We've got good news! Now you can search through our research-grade biosimilars offering effortlessly on our website. Biosimilar antibodies for research enable cost-effective study of drug effects, bypassing the need for expensive pharmaceutical-grade therapeutics. They are crucial for validating novel treatments and offer significant value in fields like immuno-oncology and autoimmunity. Simply input the keyword "Biosimilar" into the search bar on our website to access the complete list of such products. The new Biosimilar search is designed to make your search process seamless and efficient. Dive into our wide range of biosimilars today and push the boundaries of your research. https://lnkd.in/g-5rmFJa #Thermofisherscientific #research #antibodies #biosimilars